Clinical trials: Diabetes Type 2
Type 2 Diabetes Mellitus
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
To evaluate the efficacy and safety of alogliptin administered as an add-on to sulfonylurea (glimepiride) or metformin, once daily (QD), twice daily (BID) or three times daily (TID).
- Trial name
- NCT01318135
- Testing
- Alogliptin and glimepiride, Alogliptin and metformin
- Volunteers
- 576 people
- Sponsor
- Takeda
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7%…
- Trial name
- NCT01215435
- Testing
- biphasic insulin aspart 30
- Where
- Iran
- Volunteers
- 245 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
This protocol is designed to evaluate the metabolic effects of adding exenatide, rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate glycemic control.
- Trial name
- NCT00135330
- Testing
- exenatide, rosiglitazone
- Where
- 19 sites in United States
- Volunteers
- 137 people
- Sponsor
- AstraZeneca
Diabetes, Type 2
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes.
- Trial name
- NCT06340854
- Testing
- Insulin icodec, Insulin glargine
- Where
- 83 sites in United States, Bulgaria and 7 more
- Volunteers
- 412 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.
- Trial name
- NCT00516074
- Testing
- exenatide
- Where
- 6 sites in Canada, Netherlands
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Kidney Transplant, Diabetes Mellitus, Type 2
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral as part of a ATG induction, prednisone free…
- Conditions
- Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
- Trial name
- NCT00296296
- Testing
- Cyclosporin, Tacrolimus, 'Diabetes Education / Management'
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Stanford University
Type 2 Diabetes Mellitus
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).
- Trial name
- GRAND-307 (NCT01647542)
- Testing
- TAK-875
- Where
- 51 sites in Australia, China and 3 more
- Volunteers
- 393 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 2
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
This study is conducted in Europe. The aim of the study is to compare the effect of semaglutide subcutaneous (s.c., under the skin) 1.0 mg once-weekly to liraglutide s.c.1.2 mg once-daily on blood sugar levels after 30 weeks of…
- Trial name
- SUSTAIN 10 (NCT03191396)
- Testing
- Semaglutide, Liraglutide
- Where
- 92 sites in Bulgaria, Czechia and 10 more
- Volunteers
- 577 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
- Trial name
- NCT00839527
- Testing
- albiglutide, metformin, glimepiride
- Where
- 358 sites in United States, Germany and 7 more
- Volunteers
- 685 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus, Obesity
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (>1.8 units/kg/day) in patients with uncontrolled (HbA1c >7.5%) type 2 diabetes mellitus will improve blood…
- Trial name
- NCT01505673
- Testing
- Liraglutide, Saline
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Ildiko Lingvay
Type II Diabetes Mellitus
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
This is a multicenter randomized, double-blind, placebo- and active-controlled (liraglutide; Victoza®), parallel-group, clinical trial of MK-8521 in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic…
- Trial name
- NCT02492763
- Testing
- MK-8521, Liraglutide, Metformin
- Volunteers
- 176 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes.
- Trial name
- NCT01029704
- Testing
- EGT0001442
- Where
- 12 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)
The purpose of the study is to determine whether in patients with early type 2 diabetes,a short-term intensive metabolic intervention comprising of sitagliptin, metformin, basal insulin glargine and lifestyle approaches will be…
- Trial name
- NCT02623998
- Testing
- insulin glargine, sitagliptin/metformin, lifestyle therapy
- Where
- 6 sites in Canada
- Volunteers
- 102 people
- Sponsor
- Population Health Research Institute
Hypercholesterolemia, Mixed Dyslipidemia
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
The purpose of this study is to evaluate the effect of 12 weeks of subcutaneous evolocumab taken monthly compared with subcutaneous placebo taken monthly on low density lipoprotein cholesterol (LDL-C) in adults with type 2…
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Trial name
- BANTING (NCT02739984)
- Testing
- Evolocumab
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 424 people
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Type 2
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
This is a multi-center, open-label study to assess the feasibility and preliminary safety of the Endogenex Device for endoscopic duodenal mucosal regeneration in patients with type 2 Diabetes inadequately controlled on 2-3…
- Conditions
- Diabetes, Diabetes Type 2, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
- Trial name
- REGENT-1-US (NCT05014204)
- Testing
- The Endogenex Device
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endogenex, Inc.
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOPE (NCT00510952)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.